AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPTHEA LTD

0.600

+0.000

Volume:- -

Turnover:- -

Market Cap:738.77M

PE:-1.46

High:0.600

Open:0.600

Low:0.600

Close:0.600

Loading ...

Overview Company News Filings

Opthea Ltd - There Remains Material Uncertainty as to Opthea's Ability to Continue as a Going Concern

THOMSON REUTERS

Why this sold-off ASX All Ords dividend stock is 'well placed to generate long-term shareholder value'

Australian Shares Rise as Trump Signals Tariff Leniency; Endeavour to Undergo Overhaul as New Executive Chairman Leads Review

MT Newswires Live

HM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%

MT Newswires Live

Trading in Opthea Still Halted After Phase 3 Study Failure

Opthea Ltd : H.c. Wainwright Cuts Target Price to $2 From $12

THOMSON REUTERS

BUZZ-Australia's Regal Asian Investments falls on devaluing Opthea stake

Opthea Ltd : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $1 From $12

THOMSON REUTERS

Regal Confirms Stake in Opthea

MT Newswires Live

Opthea Announces Coast Phase 3 Trial Topline Results

THOMSON REUTERS

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Raises 'Going Concern' Doubts

MT Newswires Live

Opthea’s Phase 3 trial results fail to help patients, future of company at risk

The Market Herald

Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025

The Market Herald

BRIEF-Opthea Say Coast Phase 3 Trial Fails To Meet Primary Endpoint

Opthea Ltd - Coast Phase 3 Trial Fails to Meet Primary Endpoint

THOMSON REUTERS

Wednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025

The Market Herald

ASX Market Open: Bounceback to survive a second day Down Under | March 18, 2025

The Market Herald

Trading in Opthea Halted Ahead of Update on Wet AMD Study

Monday’s HotCopper Trends: Spartan and Ramelius merger, Arizona capital raise | March 17, 2025

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OPT.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.6,"timestamp":1745302320000,"preClose":0.6,"halted":0,"volume":0,"delay":0,"nameEN":"OPTHEA LTD","floatShares":786007538,"shares":1231287336,"eps":-0.4113646915737952,"marketStatus":"Closed","change":0,"latestTime":"04-22 16:12:00 AEST","open":0.6,"high":0.6,"low":0.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.4113646915737952,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.6,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786007538,"roa":"-73.34%","roe":"-3383.08%","lyrEps":-0.539481,"shares":1231287336,"dividePrice":0,"high":0.6,"amplitude":0,"preClose":0.6,"low":0.6,"week52Low":0.335,"pbRate":"-2.80","psRate":"2262.68","week52High":1.165,"institutionHeld":0,"latestPrice":0.6,"eps":-0.4113646915737952,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.4113646915737952,"open":0.6,"prevYearClose":0.81,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.6,"sixtyDayClose":0.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523393238","title":"Opthea Ltd - There Remains Material Uncertainty as to Opthea's Ability to Continue as a Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2523393238","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523393238?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:42","pubTimestamp":1743385329,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC03L:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2522532974","title":"Why this sold-off ASX All Ords dividend stock is 'well placed to generate long-term shareholder value'","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532974","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532974?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:30","pubTimestamp":1743107400,"startTime":"0","endTime":"0","summary":"ASX All Ords dividend stock Regal Partners Ltd  is having a wild ride this week. Shares in the All Ordinaries Index  listed alternative investment manager closed down 8.85% on Thursday at $2.37. That followed on a gain of 2.4% on Wednesday and a gain of 5.4% on Tuesday. All of which followed a painful 14.8% decline on Monday. Why the big fall in Regal Partners shares on Monday?Monday's big sell-off in the ASX All Ords dividend stock followed on concerning news from eye treatment company Opthea Limited . Opthea reported that its phase 3 COAST clinical trial had failed to meet its primary goal. And as the Motley Fool's Bronwyn Allen noted, \"The failure of the trial raises serious financial concerns for Opthea.\" Indeed, Opthea stated, \"In light of these matters, there remains material uncertainty as to Opthea's ability to continue as a going concern.\" So, why were investors selling Regal Partners shares on the news?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/28/why-this-sold-off-asx-all-ords-dividend-stock-is-well-placed-to-generate-long-term-shareholder-value/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK4139","OPT","OPT.AU","BK7508","RPL.AU","BK7062","XAO.AU"],"gpt_icon":0},{"id":"2522894535","title":"Australian Shares Rise as Trump Signals Tariff Leniency; Endeavour to Undergo Overhaul as New Executive Chairman Leads Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2522894535","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522894535?lang=en_us&edition=fundamental","pubTime":"2025-03-26 13:59","pubTimestamp":1742968778,"startTime":"0","endTime":"0","summary":"Australian stocks rose on Wednesday as US President Trump signaled that his tariff plans would likely take a lenient approach.The S&P/ASX 200 Index rose 0.7% or 56.5 points to close at 7,999.Trump sai","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","HM1.AU","XJO.AU","BK7083","XKO.AU","BK7040","OPT.AU","BK7067","PDN.AU","XAO.AU","BK7509","EDV.AU"],"gpt_icon":0},{"id":"2522083015","title":"HM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522083015","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522083015?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:49","pubTimestamp":1742946561,"startTime":"0","endTime":"0","summary":"Hearts and Minds Investments  said its revaluation of the holding value of Opthea  in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.The revaluation takes into account the study results, as well as the potential for a \"positive outcome\" from the upcoming trial readout.The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.Opthea said Monday that its Combination OPT-302 with Aflibercept  study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.Shares of the company rose 1% in recent Wednesday trade.Price : $3.05, Change: $+0.040, Percent Change: +1.33%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAV","BK7508","BK7067","OPT","HM1.AU","BK4139","OPT.AU"],"gpt_icon":0},{"id":"2522072540","title":"Trading in Opthea Still Halted After Phase 3 Study Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2522072540","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522072540?lang=en_us&edition=fundamental","pubTime":"2025-03-26 00:43","pubTimestamp":1742920980,"startTime":"0","endTime":"0","summary":"Trading in shares of Opthea remains halted in the U.S. and Australia after the clinical-stage biopharmaceutical company said its lead product candidate, sozinibercept, failed in a late-stage study in wet age-related macular degeneration, or wet AMD.Opthea on Monday said the Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision, missed its primary endpoint of mean change in best corrected visual acuity.Opthea said it is considering the impact of the negative study results under its development funding agreement, adding that it may be required to pay amounts to the investors that would have a material adverse impact on its solvency, and that there is material uncertainty about its ability to continue as a going concern.The company said it is in talks with its development funding investors to determine the most appropriate course of action, and that it has requested that trading in its securities re","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4585","LU1951200564.SGD","LU0823434740.USD","BK4612","LU0109392836.USD","BK4573","LU1242518857.USD","LU0056508442.USD","IE00BMPRXR70.SGD","LU0823421416.USD","BK4139","LU0889565833.HKD","BK4512","LU1923623000.USD","IE0009356076.USD","BK4575","LU0979878070.USD","OPT","LU1988902786.USD","LU2054465674.USD","LU2264538146.SGD","LU1316542783.SGD","LU0127658192.USD","LU2098885051.SGD","BK4141","LU0823421333.USD","LU2250418816.HKD","LU0823434583.USD","BK4566","LU1852331112.SGD","BK4605","BK4614","LU2458330243.SGD","LU1064131342.USD","LU1989764664.SGD","LU1303367103.USD","BK4532","LU0390134368.USD","IE0004445239.USD","BK4529","LU1951198990.SGD","OPT.AU","BK4554","IE00BMPRXN33.USD","LU0719512351.SGD","LU0082616367.USD","LU1803068979.SGD","BK4588"],"gpt_icon":1},{"id":"2522203520","title":"Opthea Ltd : H.c. Wainwright Cuts Target Price to $2 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2522203520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522203520?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:20","pubTimestamp":1742905248,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q814H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OPT.AU","BK4139","OPT"],"gpt_icon":0},{"id":"2522054302","title":"BUZZ-Australia's Regal Asian Investments falls on devaluing Opthea stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2522054302","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522054302?lang=en_us&edition=fundamental","pubTime":"2025-03-25 11:36","pubTimestamp":1742873771,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Regal Asian Investments falls on devaluing Opthea stake** Shares of Regal Asian Investments RG8.AX fall as much as 3.8% to A$1.915, their lowest level since Dec 8, 2023** Stock posts biggest intraday decline since Feb 20** Investment manager devalues stake in biotech Opthea OPT.AX to A$0.20/shr vs OPT's last close of A$0.60 before trading was suspended** OPT on Monday warned of insolvency after its late-stage trial for its wet age-related macular degeneration injection failed** RG8 stock last down 2%, bringing YTD losses to 8.9%.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL6N3Q806O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","RG8.AU","OPT.AU"],"gpt_icon":0},{"id":"2522594470","title":"Opthea Ltd : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $1 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2522594470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522594470?lang=en_us&edition=fundamental","pubTime":"2025-03-25 11:22","pubTimestamp":1742872926,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q71N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OPT","BK4139","OPT.AU"],"gpt_icon":0},{"id":"2522803268","title":"Regal Confirms Stake in Opthea","url":"https://stock-news.laohu8.com/highlight/detail?id=2522803268","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522803268?lang=en_us&edition=fundamental","pubTime":"2025-03-25 09:55","pubTimestamp":1742867733,"startTime":"0","endTime":"0","summary":"Regal Investment Fund  investment manager, Regal Funds Management, confirmed that it holds a 5.6% stake in Opthea  prior to the biopharmaceutical company's results of its study, according to a Tuesday filing with the Australian bourse.Opthea said Monday that its Combination OPT-302 with Aflibercept  study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4139","BK7067","OPT.AU","OPT","RF1.AU"],"gpt_icon":0},{"id":"2521561297","title":"Opthea Announces Coast Phase 3 Trial Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521561297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521561297?lang=en_us&edition=fundamental","pubTime":"2025-03-24 12:01","pubTimestamp":1742788860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA1HRPVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2521756759","title":"Opthea Announces COAST Phase 3 Trial Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521756759","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521756759?lang=en_us&edition=fundamental","pubTime":"2025-03-24 12:01","pubTimestamp":1742788860,"startTime":"0","endTime":"0","summary":"COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52. Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern. The global COAST Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 2 mg aflibercept, as per label, every eight weeks after a loading phase for the treatment of wet AMD. The trial did not meet its primary endpoint of mean change in best corrected visual acuity  from baseline to week 52.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-announces-coast-phase-3-040100859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Opthea Announces COAST Phase 3 Trial Topline Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4543","LU1988902786.USD","LU1880398471.USD","IE0009356076.USD","LU0109392836.USD","BK4612","LU2458330169.SGD","LU0889565833.HKD","LU1951200564.SGD","LU0056508442.USD","BK4588","IE00BMPRXR70.SGD","LU1852331112.SGD","BK4532","GFS","LU1989764664.SGD","LU2360106780.USD","BK4554","LU0823434740.USD","LU0979878070.USD","LU1242518931.SGD","LU1316542783.SGD","LU1923623000.USD","LU1803068979.SGD","IE00BMPRXN33.USD","LU0081259029.USD","BK4585","IE00B5949003.HKD","BK4529","LU0390134368.USD","LU2264538146.SGD","BK4566","BK4534","LU1880398554.USD","BK4573","LU2458330243.SGD","BK4605","LU0719512351.SGD","LU1951198990.SGD","LU2250418816.HKD","LU0642271901.SGD","LU1064131342.USD","OPT.AU","LU2054465674.USD","LU2098885051.SGD","LU0082616367.USD","BK4139","OPT","IE0004445239.USD","LU1242518857.USD"],"gpt_icon":1},{"id":"2521732916","title":"Opthea Raises 'Going Concern' Doubts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521732916","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521732916?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:36","pubTimestamp":1742783798,"startTime":"0","endTime":"0","summary":"Opthea  said its Combination OPT-302 with Aflibercept  study in patients with wet age-related Macular Degeneration, failed to meet its primary endpoint, according to a Monday filing with the Australian bourse.The biopharmaceutical company is now reviewing its obligations under its development funding agreement  with investors, the filing said.Under the DFA, Opthea could face repayment obligations of up to $680 million, if the agreement is terminated, due to factors like failure to advance its drug sozinibercept, used in the trial, the filing added.Discussions with the DFA investors are ongoing for the parties to come to an agreement, including a negotiated settlement, however, no decision has been made regarding the continuation of the trial, the company said.Given uncertainties regarding the trial and a reported $113.8 million in cash, the company added there is significant doubt about its ability to continue as a going concern.Opthea requested an extension of trading suspensions on t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","XAO.AU","XKO.AU","BK7067","BK7508","OPT","BK4139","XJO.AU"],"gpt_icon":0},{"id":"2521531157","title":"Opthea’s Phase 3 trial results fail to help patients, future of company at risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2521531157","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521531157?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:15","pubTimestamp":1742782500,"startTime":"0","endTime":"0","summary":"It mightn’t be too surprising Opthea  applied for a voluntary suspension last week ahead of Monday’s Phase 3 trial results – they throw the future of the company into question.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.“[The] COAST Phase 3 trial failed to meet primary endpoint of mean change … from baseline,” the company wrote of its retinal disease trial.The problem is, with a Development Funding Agreement backed by investors, the company is now unsure whether or not it has a future at all. Phase 3 trials are the be-all-end-all study that typically precedes an FDA approval.“In light of these matters, there remains material uncertainty as to Opthea’s ability to continue as a going concern,” Opthea wrote on Monday.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/optheas-phase-3-trial-results-fail-to-help-patients-future-of-company-at-risk-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LU0082616367.USD","BK4139","LU0642271901.SGD","BK4512","BK4543","LU1316542783.SGD","LU0823421333.USD","BK4575","LU0198837287.USD","LU1988902786.USD","IE00BMPRXR70.SGD","BK4534","BK4566","LU2054465674.USD","LU0979878070.USD","LU0056508442.USD","LU2458330169.SGD","LU1951200564.SGD","LU2264538146.SGD","LU1852331112.SGD","LU1303367103.USD","LU0889565833.HKD","BK4532","BK4554","LU0081259029.USD","BK4605","LU0823434583.USD","OPT","LU0823434740.USD","OPT.AU","LU1880398471.USD","BK4588","BK7067","IE0009356076.USD","IE00BMPRXN33.USD","LU0390134368.USD","IE00B5949003.HKD","LU2250418816.HKD","BK4585","LU0127658192.USD","IE0004445239.USD","BK4612","LU1923623000.USD","LU1989764664.SGD","LU1803068979.SGD","LU0823421416.USD","BK7508","LU1951198990.SGD","LU1064131342.USD"],"gpt_icon":1},{"id":"2521734542","title":"Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521734542","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521734542?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:13","pubTimestamp":1742782380,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,928 points.Discretionary has been the best performing sector today, up 1%, followed by Financials, up 0.66%, and Utilities, up 0.5%.Staples has been the worst performing, down 1%, followed by Materials, down 0.9%, and Industrials, down 0.8%.Opthea  has been the most watched on HotCopper forums today and is in a trading halt. Its COAST Phase 3 trial failed to meet primary endpoint of mean change in best corrected visual acuity from baseline to Week 52. The company is now considering the overall impact of the negative trial result heading into the year.Also trending: Errawarra Resources , which has entered binding agreements to acquire 70% of the historical Elizabeth Hill Silver Project, 70% of the silver rights to the Pinderi Hills Project tenement package, and 70% of the ownership of three tenements surrounding the silver project.Rounding out the most discussed has been Memphasys , which unveiled the successful unblinding and data analysis of i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-opthea-strife-errawarra-jumps-on-acquisitions-memphasys-best-in-class-trial-results-march-21-2025-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7048","MEM.AU","OPT","BK7067","BK7095","ERW.AU","MEM","OPT.AU","BK7508"],"gpt_icon":0},{"id":"2521735610","title":"BRIEF-Opthea Say Coast Phase 3 Trial Fails To Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2521735610","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521735610?lang=en_us&edition=fundamental","pubTime":"2025-03-24 09:14","pubTimestamp":1742778886,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Say Coast Phase 3 Trial Fails To Meet Primary EndpointMarch 24 (Reuters) - Opthea Ltd OPT.AX:COAST PHASE 3 TRIAL FAILS TO MEET PRIMARY ENDPOINTFurther company coverage: OPT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q503G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2521787186","title":"Opthea Ltd - Coast Phase 3 Trial Fails to Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2521787186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521787186?lang=en_us&edition=fundamental","pubTime":"2025-03-24 07:42","pubTimestamp":1742773328,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250323:nFWN3Q503G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2520930569","title":"Wednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520930569","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520930569?lang=en_us&edition=fundamental","pubTime":"2025-03-19 09:57","pubTimestamp":1742349420,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,864 points.Financials has been the best performing sector, up 0.3%, followed by Materials, up 0.15% and Energy, up 0.1%.Utilities has been the worst performer, down 1.1%, followed by Industrials and Staples, both down 0.55%.Opthea  has been the most watched on HotCopper forums today. The company is in a voluntary suspension pending the release of top line results of its COAST clinical trial.Also trending Imugene  has revealed the US Food and Drug Administration has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel , for the treatment of relapsed or refractory diffuse large B-cell lymphoma .Rounding out the most discussed is Arizona Lithium  after kicking off a share purchase plan to raise $2 million to advance the Prairie project.You’re up to date, see you later for market close.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/wednesdays-hotcopper-trends-imugene-scores-fda-tick-arizona-kicks-off-share-purchase-plan-march-19-2025-2025-03-19/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["AZL.AU","BK7095","BK7508","BK7507","OPT.AU","BK7504","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2520138689","title":"ASX Market Open: Bounceback to survive a second day Down Under | March 18, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520138689","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520138689?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:10","pubTimestamp":1742245800,"startTime":"0","endTime":"0","summary":"Week 12’s global rally is holding firm early this Tuesday morning, with ASX 200 futures pointing to a +0.83% gain  when trade begins at 10am in Sydney.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.It’s not the only rally everyone’s watching either – after nudging around the historic high several times, gold is trading above $3,000 an ounce today for the very first time. For many, the safe haven asset has been seen as a perfect way to dodge all the uncertainty fuelled by Trump and his tariffs in the short term.Though there has been a rush towards gold, stocks have enjoyed a green bounceback through Monday and Tuesday this week too: Today, all three major U.S. indices returned some recent losses. The Dow Jones led the way, up 0.8%.So too Mineral Resources  after the leading miner just scored a “buy” upgrade from UBS that sparked a lithium and battery metals stock rally.That’s Market","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-bounceback-to-survive-a-second-day-down-under-march-18-2025-2025-03-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7504","NAB.AU","OPT.AU","BK7135","BK7507","BK7067","WBC.AU","MIN.AU","BK7508","BK7511","BK7095"],"gpt_icon":0},{"id":"2520795515","title":"Trading in Opthea Halted Ahead of Update on Wet AMD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2520795515","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520795515?lang=en_us&edition=fundamental","pubTime":"2025-03-17 23:26","pubTimestamp":1742225160,"startTime":"0","endTime":"0","summary":"Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD.In a filing with the Australian Securities Exchange Monday, Opthea requested the trading halt pending an announcement related to top-line results of a Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision.The ASX said the halt will remain in place until the start of trading Wednesday unless Opthea issues an announcement sooner.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7067","GFS","BK4588","IE0009356076.USD","BK4573","LU1880398471.USD","LU1923623000.USD","LU1242518931.SGD","LU2054465674.USD","BK4512","BK4612","LU2264538146.SGD","BK4534","LU0889565833.HKD","LU0056508442.USD","LU0642271901.SGD","LU1242518857.USD","LU1803068979.SGD","LU0109392836.USD","LU2360106780.USD","IE0004445239.USD","LU0198837287.USD","LU1316542783.SGD","BK4141","LU0823421416.USD","LU1303367103.USD","LU1852331112.SGD","LU0390134368.USD","LU0979878070.USD","LU2458330243.SGD","BK4543","OPT","LU0127658192.USD","BK4605","LU2250418816.HKD","LU0823434740.USD","BK4532","BK4566","IE00B5949003.HKD","LU0823421333.USD","LU0823434583.USD","BK4529","BK4554","BK4585","LU1988902786.USD","LU1951200564.SGD","LU0082616367.USD","BK4614"],"gpt_icon":1},{"id":"2520559489","title":"Monday’s HotCopper Trends: Spartan and Ramelius merger, Arizona capital raise | March 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520559489","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520559489?lang=en_us&edition=fundamental","pubTime":"2025-03-17 10:32","pubTimestamp":1742178720,"startTime":"0","endTime":"0","summary":"The ASX has been up 0.62% at 7,837 points, following Wall Street’s Friday lead.It’s a sea of green today and Materials has been the best performing sector, up 1.55%, followed by Energy, up 1%, and Real Estate, up 0.66%.Health Care is the one and only sector in the red, down 0.25%.Spartan Resources  has been the most watched on HotCopper forums today, with the company in advanced merger talks with Ramelius Resources . The deal is slated to be announced to the ASX as early as next week.Also trending: Opthea  has been placed in a trading halt pending a material announcement regarding top line results of its COAST  clinical trial.Rounding out the most discussed has been Arizona Lithium , which entered a trading halt pending a capital raising announcement.Meet GeoGeorge:The HotCopper poster so accurate he got hired as an analyst. The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-spartan-and-ramelius-merger-arizona-capital-raise-march-17-2025-2025-03-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["SPAQ.U","AZL.AU","BK7507","BK7504","OPT.AU","BK7508","BK7104","BK7095","SPR.AU","BK7506","RMS.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[]}}